Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin plus Sunitinib versus Placebo plus Sunitinib in Metastatic Renal Cell Carcinoma
2007-003847-66Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in clear cell renal cell carcinoma (ccRCC) comparing Enzastaurin + Sunitinib with Placebo + Sunitinib (2 arms). Primary endpoints: Safety of enzastaurin plus sunitinib (Part 1) and Progression-free survival (Part 2). Started Jan 2008; status: completed.
02
Drugs
enzastaurinsunitinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2007-003847-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003847-66.